Antimicrobial pipeline DEINOVE has an active antibiotic candidate in a Phase II trial for severe Clostridioides difficile infections, signaling a potential partner opportunity for late-stage antimicrobial development, co-development, or licensing arrangements to accelerate clinical progression.

Rare bacterial library The company maintains a unique collection of 10,000 rare strains and thousands of extracts, offering a distinctive asset for collaboration in novel antimicrobial discovery, screenings, and access programs for pharma and biotech partners.

Industrial production Development of bacterial micro-factories addresses production challenges of rare compounds, presenting opportunities for process development partnerships, scale-up collaborations, and technology licensing with manufacturing-focused firms.

Strategic partnerships Recent and ongoing collaborations with Calibr and prior industry/academic partnerships indicate a strong openness to co-development and research alliances that can be leveraged to expand joint ventures, funded programs, or milestone-driven deals.

Diversified portfolio Beyond antibiotics, DEINOVE positions in cosmetics actives and bio-based solutions, offering cross-vertical sales opportunities to cosmeceutical brands, natural products verticals, and manufacturing partners seeking sustainable bioactives.